MedPath

[11C]NNC-112

Generic Name
[11C]NNC-112

Brain Dopaminergic Signaling in Opioid Use Disorders

Early Phase 1
Recruiting
Conditions
Normal Physiology
Opioid Use Disorders
Interventions
Drug: [11C]raclopride plus drug
Drug: [11C]raclopride plus placebo
First Posted Date
2017-06-19
Last Posted Date
2025-04-30
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Target Recruit Count
360
Registration Number
NCT03190954
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112

Phase 1
Completed
Conditions
Healthy
First Posted Date
2004-07-28
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Mental Health (NIMH)
Target Recruit Count
10
Registration Number
NCT00088517
Locations
🇺🇸

National Institute of Mental Health (NIMH), Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath